BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23834124)

  • 1. Sarcoidosis associated with vemurafenib.
    Adam A; Thomas L; Bories N; Zaharia D; Balme B; Freymond N; Dalle S
    Br J Dermatol; 2013 Jul; 169(1):206-8. PubMed ID: 23834124
    [No Abstract]   [Full Text] [Related]  

  • 2. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
    Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
    Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vemurafenib-induced panniculitis.
    Villani AP; Zaharia D; Dalle S; Depaepe L; Balme B; Thomas L
    Eur J Dermatol; 2013 Apr; 23(2):258-60. PubMed ID: 23567624
    [No Abstract]   [Full Text] [Related]  

  • 4. Pyogenic granuloma as a cutaneous adverse effect of vemurafenib.
    Sammut SJ; Tomson N; Corrie P
    N Engl J Med; 2014 Sep; 371(13):1265-7. PubMed ID: 25251629
    [No Abstract]   [Full Text] [Related]  

  • 5. Vemurafenib sensitivity skin reaction after ipilimumab.
    Harding JJ; Pulitzer M; Chapman PB
    N Engl J Med; 2012 Mar; 366(9):866-8. PubMed ID: 22375995
    [No Abstract]   [Full Text] [Related]  

  • 6. Vemurafenib-induced granuloma annulare.
    Lee SB; Weide B; Ugurel S; Mössner R; Enk A; Hassel JC
    J Dtsch Dermatol Ges; 2016 Mar; 14(3):305-8. PubMed ID: 26972200
    [No Abstract]   [Full Text] [Related]  

  • 7. Second primary melanomas on treatment with vemurafenib.
    Dalle S; Poulalhon N; Debarbieux S; Thomas L
    Br J Dermatol; 2013 Apr; 168(4):887-8. PubMed ID: 23066856
    [No Abstract]   [Full Text] [Related]  

  • 8. Vemurafenib-induced eccrine squamous syringometaplasia.
    Lescoat A; Droitcourt C; Stock N; Le Gall F; Dupuy A
    Dermatology; 2013; 226(4):362-4. PubMed ID: 23860306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib.
    Ma L; Dominguez AR; Collins GR; Kia KF; Cockerell CJ
    Arch Dermatol; 2012 Dec; 148(12):1428-9. PubMed ID: 23247496
    [No Abstract]   [Full Text] [Related]  

  • 10. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
    Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
    Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
    [No Abstract]   [Full Text] [Related]  

  • 11. Unusual complication of vemurafenib treatment of metastatic melanoma: exacerbation of acantholytic dyskeratosis complicated by Kaposi varicelliform eruption.
    Gupta M; Huang V; Linette G; Cornelius L
    Arch Dermatol; 2012 Aug; 148(8):966-8. PubMed ID: 22911209
    [No Abstract]   [Full Text] [Related]  

  • 12. Second primary melanomas on treatment with vemurafenib: reply from the authors.
    Fearfield L; Newton-Bishop JA; Sinha R; Edmonds K; Gore ME; Larkin J
    Br J Dermatol; 2013 Apr; 168(4):888-9. PubMed ID: 23066884
    [No Abstract]   [Full Text] [Related]  

  • 13. Eccrine squamous syringometaplasia associated with vemurafenib therapy.
    Story SG; Beschloss JK; Dolan CK; Thomas BC
    J Am Acad Dermatol; 2012 Nov; 67(5):e208-10. PubMed ID: 23062917
    [No Abstract]   [Full Text] [Related]  

  • 14. Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases.
    Dabner M; Harvey NT; Soma A; Wood BA
    Pathology; 2012 Dec; 44(7):661-4. PubMed ID: 23172086
    [No Abstract]   [Full Text] [Related]  

  • 15. Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma.
    Boyd KP; Vincent B; Andea A; Conry RM; Hughey LC
    J Am Acad Dermatol; 2012 Dec; 67(6):1375-9. PubMed ID: 22940405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway.
    Huang V; Hepper D; Anadkat M; Cornelius L
    Arch Dermatol; 2012 May; 148(5):628-33. PubMed ID: 22431713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lupus erythematosus-like skin eruption after vemurafenib therapy.
    Reinholz M; Berking C; Hermans C; Ruzicka T; Braun-Falco M
    J Am Acad Dermatol; 2014 Oct; 71(4):e159-60. PubMed ID: 25219748
    [No Abstract]   [Full Text] [Related]  

  • 18. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.
    Braunstein I; Gangadhar TC; Elenitsas R; Chu EY
    J Cutan Pathol; 2014 Jun; 41(6):539-43. PubMed ID: 24517243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.
    Regnier-Rosencher E; Lazareth H; Gressier L; Avril MF; Thervet E; Dupin N
    Br J Dermatol; 2013 Oct; 169(4):934-8. PubMed ID: 23909652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the adnexal epithelium: an unusual case of syringometaplasia in a patient on vemurafenib.
    Yu J; Ravikumar S; Plaza JA; Troy JL; Schieke SM
    Am J Dermatopathol; 2015 May; 37(5):e57-60. PubMed ID: 25839889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.